Emergent Biosolutions Profit Margin

The latest profit margin for EBS is -23.84% as of June 2026. That compares with 16.97% in the prior-year period — down 240.4% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Emergent Biosolutions's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBS's profit margin moved from 16.97% to -23.84% — a 240.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Emergent Biosolutions's valuation or profitability profile.

Against Healthcare companies, EBS currently prints -23.84% for profit margin, while the sector average sits near 14.41%. That is roughly 265.4% below the sector mean. Large gaps often invite a closer look at Emergent Biosolutions's growth, margins, and balance sheet.

Profit Margin shows how effectively Emergent Biosolutions converts resources into returns. At -23.84%, EBS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 16.97% in the prior-year period — down 240.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting EBS's profit margin (-23.84%), review year-over-year change from 16.97%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.